Since AstraZeneca announced that its revenues and profits have continued to grow, nothing has been the same within the company. Just a few days after this announcement, the pharmaceutical group entered into collaboration with the American company Eko. Later, it was the President of Argentina, Alberto Fernandez, who announced that Mexico and his country will now produce AstraZeneca's Covid-19 vaccine. This Friday, the laboratory reached an agreement with Brussels for vaccine doses. Here is what is happening with this famous agreement.
The announcement came from the biopharmaceutical company AstraZeneca itself on Friday. According to what the group has implied, it has signed an agreement with the European Commission with a rather specific purpose. Indeed, this agreement concerns the supply of more than 400 million doses of a brand new vaccine as soon as it becomes available. AstraZeneca has particularly stressed that this is its famous vaccine against Covid-19: AZD1222 vaccine.
This new agreement is based on the existing agreement with the Inclusive Vaccines Alliance led by France, Germany, the Netherlands and Italy. The pharmaceutical group has also clarified the purpose of this important agreement. According to its details, it will give all EU Member States the opportunity to have access to the vaccine, but on an equitable basis. It must also be said that these countries will have this access without any profit during the pandemic period.
The pharmaceutical group AstraZeneca, which is well known for the production of several vaccines against multiple diseases, gave other no less important details. By the way, the laboratory pointed out that the clinical development of AZD1222 is proceeding smoothly. In particular, it is marked by advanced Phase II/III trials underway in both Brazil and the United Kingdom. The results of these various trials are expected to be published by the end of the year.
Long before the agreement unveiled this Friday by AstraZeneca, on August 13, the Argentinean president announced another agreement to produce the laboratory's vaccine. Indeed, the latter was signed between the British laboratory and the biotechnology company mAbxience. It includes the transfer of the technology needed to produce more than 150 million doses of vaccine to satisfy all of South America. The president said the exception was Brazil.
According to Fernandez's statement, production for Latin America will be handled by Mexico and Argentina. According to the president, this will allow quick and efficient access to the vaccine for all countries in the region. In his statement, he said that this famous contract gives Argentina the opportunity to have the vaccine available when it needs it. All this at a reasonable price. These two agreements come after AstraZeneca's H1 results.
The laboratory's revenues were up 12% to $12.6 billion and its earnings per share were up 24% to $2.01. Sales of new drugs improved by 42% to $6.4 billion according to figures reported by AstraZeneca.